{"name":"Bausch Health Companies Inc.","slug":"bausch","ticker":"BHC","exchange":"NYSE","domain":"bauschhealth.com","description":"Bausch Health Companies Inc. is a global, diversified Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. \nBausch Health manufactures and markets branded pharmaceuticals, generic pharmaceuticals, and over-the-counter products directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America.","hq":"Laval, Quebec, Canada","founded":0,"employees":"20300","ceo":"Thomas Appio","sector":"Specialty Pharma","stockPrice":5.36,"stockChange":0.1,"stockChangePercent":1.9,"marketCap":"$2.0B","metrics":{"revenue":8724000000,"revenueGrowth":9.3,"grossMargin":70.7,"rdSpend":0,"netIncome":157000000,"cash":1308999936,"dividendYield":0,"peRatio":12.8,"fiscalYear":"FY2017"},"revenueBreakdown":[{"name":"Xifaxan","genericName":"rifaximin","slug":"rifaximin","revenue":1500000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"1946-01-01","label":"Migranal first approved","drug":"Migranal","drugSlug":"dihydroergotamine","type":"approval","sentiment":"positive"},{"date":"1953-01-01","label":"Levo-Dromoran first approved","drug":"Levo-Dromoran","drugSlug":"levorphanol","type":"approval","sentiment":"positive"},{"date":"1954-01-01","label":"Mysoline first approved","drug":"Mysoline","drugSlug":"primidone","type":"approval","sentiment":"positive"},{"date":"1954-01-01","label":"Oxsoralen-Ultra first approved","drug":"Oxsoralen-Ultra","drugSlug":"methoxsalen","type":"approval","sentiment":"positive"},{"date":"1960-01-01","label":"Chlordiazepoxide Hydrochloride first approved","drug":"Chlordiazepoxide Hydrochloride","drugSlug":"chlordiazepoxide","type":"approval","sentiment":"positive"},{"date":"1967-01-01","label":"Edecrin first approved","drug":"Edecrin","drugSlug":"ethacrynic-acid","type":"approval","sentiment":"positive"},{"date":"1971-01-01","label":"Ancobon first approved","drug":"Ancobon","drugSlug":"flucytosine","type":"approval","sentiment":"positive"},{"date":"1971-01-01","label":"Retin-A first approved","drug":"Retin-A","drugSlug":"tretinoin","type":"approval","sentiment":"positive"},{"date":"1973-01-01","label":"Testred first approved","drug":"Testred","drugSlug":"methyltestosterone","type":"approval","sentiment":"positive"},{"date":"1982-01-01","label":"Locoid first approved","drug":"Locoid","drugSlug":"hydrocortisone-butyrate","type":"approval","sentiment":"positive"},{"date":"1982-01-01","label":"Loprox first approved","drug":"Loprox","drugSlug":"ciclopirox","type":"approval","sentiment":"positive"},{"date":"1985-01-01","label":"Cesamet first approved","drug":"Cesamet","drugSlug":"nabilone","type":"approval","sentiment":"positive"},{"date":"1985-01-01","label":"Syprine first approved","drug":"Syprine","drugSlug":"trientine","type":"approval","sentiment":"positive"},{"date":"1989-01-01","label":"Optipranolol first approved","drug":"Optipranolol","drugSlug":"metipranolol","type":"approval","sentiment":"positive"},{"date":"1991-01-01","label":"Dermatop first approved","drug":"Dermatop","drugSlug":"prednicarbate","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Aldara first approved","drug":"Aldara","drugSlug":"imiquimod","type":"approval","sentiment":"positive"},{"date":"1998-01-01","label":"Lotemax first approved","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"approval","sentiment":"positive"},{"date":"1999-01-01","label":"Targretin first approved","drug":"Targretin","drugSlug":"bexarotene","type":"approval","sentiment":"positive"},{"date":"2000-01-01","label":"Visudyne first approved","drug":"Visudyne","drugSlug":"verteporfin","type":"approval","sentiment":"positive"},{"date":"2001-01-01","label":"Elidel first approved","drug":"Elidel","drugSlug":"pimecrolimus","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Macugen first approved","drug":"Macugen","drugSlug":"pegaptanib","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Xibrom first approved","drug":"Xibrom","drugSlug":"bromfenac","type":"approval","sentiment":"positive"},{"date":"2008-01-01","label":"Xenazine first approved","drug":"Xenazine","drugSlug":"tetrabenazine","type":"approval","sentiment":"positive"},{"date":"2009-01-01","label":"Bepreve first approved","drug":"Bepreve","drugSlug":"bepotastine","type":"approval","sentiment":"positive"},{"date":"2009-01-01","label":"Besivance first approved","drug":"Besivance","drugSlug":"besifloxacin","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Luzu first approved","drug":"Luzu","drugSlug":"luliconazole","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Jublia first approved","drug":"Jublia","drugSlug":"efinaconazole","type":"approval","sentiment":"positive"},{"date":"2016-01-01","label":"Xiidra first approved","drug":"Xiidra","drugSlug":"lifitegrast","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Vyzulta first approved","drug":"Vyzulta","drugSlug":"latanoprostene-bunod","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Loteprednol Etabonate first approved","drug":"Loteprednol Etabonate","drugSlug":"loteprednol","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Miebo first approved","drug":"Miebo","drugSlug":"perfluorohexyloctane","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-02","label":"Xifaxan patent expiry (Compound)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-01","label":"Xifaxan Phase 3 readout (Hepatic Encephalopathy)","drug":"Xifaxan","drugSlug":"rifaximin","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-02-26","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-02-26","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-02-26","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-02-26","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-07-18","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-07-24","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-07-24","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-07-24","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-07-24","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-07-24","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-07-24","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-07-24","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-07-24","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-08-18","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2029-08-18","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2029-10-02","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-10-02","label":"Xifaxan patent expiry (Method of Use)","drug":"Xifaxan","drugSlug":"rifaximin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-12-11","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2029-12-11","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2029-12-11","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2029-12-11","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2029-12-11","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2030-04-30","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2030-04-30","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2030-04-30","label":"Aldara patent expiry (Method of Use)","drug":"Aldara","drugSlug":"imiquimod","type":"patent_expiry","sentiment":"negative"},{"date":"2030-12-31","label":"Xifaxan Phase 2 readout (Irritable Bowel Syndrome, Fecal Microbiota Transplantation)","drug":"Xifaxan","drugSlug":"rifaximin","type":"phase3_readout","sentiment":"neutral"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Method of Use)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-05-03","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-01-26","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-12-23","label":"Lotemax patent expiry (Formulation)","drug":"Lotemax","drugSlug":"loteprednol-etabonate","type":"patent_expiry","sentiment":"negative"},{"date":"2038-08-22","label":"Retin-A patent expiry (Formulation)","drug":"Retin-A","drugSlug":"tretinoin","type":"patent_expiry","sentiment":"negative"},{"date":"2038-08-22","label":"Retin-A patent expiry (Method of Use)","drug":"Retin-A","drugSlug":"tretinoin","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Botox patent cliff ($1.5B at risk)","drug":"Botox","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Solodyn patent cliff ($400M at risk)","drug":"Solodyn","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":1500000000,"percentOfTotal":100,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Xifaxan","genericName":"rifaximin","slug":"rifaximin","indication":"Diarrhea due to E. Coli","status":"marketed","revenue":1500000000},{"name":"Ancobon","genericName":"FLUCYTOSINE","slug":"flucytosine","indication":"Serious Candida Infections","status":"marketed"},{"name":"Besivance","genericName":"BESIFLOXACIN","slug":"besifloxacin","indication":"Bacterial conjunctivitis","status":"marketed"},{"name":"Jublia","genericName":"EFINACONAZOLE","slug":"efinaconazole","indication":"Onychomycosis due to Trichophyton mentagrophytes","status":"marketed"},{"name":"Loteprednol Etabonate","genericName":"LOTEPREDNOL","slug":"loteprednol","indication":"allergic conjunctivitis","status":"marketed"},{"name":"Luzu","genericName":"LULICONAZOLE","slug":"luliconazole","indication":"Tinea corporis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"immunology","drugs":[{"name":"Cesamet","genericName":"NABILONE","slug":"nabilone","indication":"Nausea and Vomiting from Chemotherapy","status":"marketed"},{"name":"Bepreve","genericName":"BEPOTASTINE","slug":"bepotastine","indication":"Allergic conjunctivitis","status":"marketed"},{"name":"Locoid","genericName":"HYDROCORTISONE BUTYRATE","slug":"hydrocortisone-butyrate","indication":"Other","status":"marketed"},{"name":"Loprox","genericName":"CICLOPIROX","slug":"ciclopirox","indication":"Onychomycosis Treatment","status":"marketed"},{"name":"Syprine","genericName":"TRIENTINE","slug":"trientine","indication":"Wilson's Disease","status":"marketed"},{"name":"Xenazine","genericName":"TETRABENAZINE","slug":"tetrabenazine","indication":"Huntington's chorea","status":"marketed"},{"name":"Xiidra","genericName":"LIFITEGRAST","slug":"lifitegrast","indication":"Tear film insufficiency","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"respiratory","drugs":[{"name":"Aldara","genericName":"IMIQUIMOD","slug":"imiquimod","indication":"Actinic keratosis","status":"marketed"},{"name":"Dermatop","genericName":"PREDNICARBATE","slug":"prednicarbate","indication":"Atopic dermatitis","status":"marketed"},{"name":"Retin-A","genericName":"TRETINOIN","slug":"tretinoin","indication":"Acne vulgaris","status":"marketed"},{"name":"Targretin","genericName":"BEXAROTENE","slug":"bexarotene","indication":"Primary cutaneous T-cell lymphoma","status":"marketed"},{"name":"Testred","genericName":"METHYLTESTOSTERONE","slug":"methyltestosterone","indication":"Bilateral Anorchia","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Visudyne","genericName":"VERTEPORFIN","slug":"verteporfin","indication":"Choroidal retinal neovascularization","status":"marketed"},{"name":"Lotemax","genericName":"LOTEPREDNOL ETABONATE","slug":"loteprednol-etabonate","indication":"Steroid-responsive inflammatory conditions of the eye","status":"marketed"},{"name":"Macugen","genericName":"pegaptanib","slug":"pegaptanib","indication":"Exudative age-related macular degeneration","status":"marketed"},{"name":"Miebo","genericName":"PERFLUOROHEXYLOCTANE","slug":"perfluorohexyloctane","indication":"Dry Eye Disease","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Chlordiazepoxide Hydrochloride","genericName":"CHLORDIAZEPOXIDE","slug":"chlordiazepoxide","indication":"Alcohol withdrawal delirium","status":"marketed"},{"name":"Migranal","genericName":"DIHYDROERGOTAMINE","slug":"dihydroergotamine","indication":"Cluster headache syndrome","status":"marketed"},{"name":"Mysoline","genericName":"PRIMIDONE","slug":"primidone","indication":"Bipolar disorder in remission","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"rare","drugs":[{"name":"Edecrin","genericName":"ETHACRYNIC ACID","slug":"ethacrynic-acid","indication":"Edema in Congestive Heart Failure","status":"marketed"},{"name":"Optipranolol","genericName":"METIPRANOLOL","slug":"metipranolol","indication":"Ocular hypertension","status":"marketed"},{"name":"Vyzulta","genericName":"LATANOPROSTENE BUNOD","slug":"latanoprostene-bunod","indication":"Ocular hypertension","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Levo-Dromoran","genericName":"LEVORPHANOL","slug":"levorphanol","indication":"Severe Pain Management","status":"marketed"},{"name":"Xibrom","genericName":"BROMFENAC","slug":"bromfenac","indication":"Pain","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Elidel","genericName":"PIMECROLIMUS","slug":"pimecrolimus","indication":"Atopic dermatitis","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"Oxsoralen-Ultra","genericName":"METHOXSALEN","slug":"methoxsalen","indication":"Palliative treatment of CTCL skin manifestations","status":"marketed"}]}],"pipeline":[{"name":"Xifaxan","genericName":"rifaximin","slug":"rifaximin","phase":"marketed","mechanism":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","indications":["Diarrhea due to E. Coli","Hepatic encephalopathy","Irritable bowel syndrome with diarrhea"],"catalyst":""},{"name":"Cesamet","genericName":"NABILONE","slug":"nabilone","phase":"marketed","mechanism":"Cannabinoid receptor 1","indications":["Nausea and Vomiting from Chemotherapy"],"catalyst":""},{"name":"Chlordiazepoxide Hydrochloride","genericName":"CHLORDIAZEPOXIDE","slug":"chlordiazepoxide","phase":"marketed","mechanism":"Histamine H1 receptor","indications":["Alcohol withdrawal delirium","Alcohol withdrawal syndrome","Anxiety","Anxiety associated with Menopause","General anesthesia"],"catalyst":""},{"name":"Levo-Dromoran","genericName":"LEVORPHANOL","slug":"levorphanol","phase":"marketed","mechanism":"Levorphanol binds primarily to mu-opioid receptors to produce analgesia, with no ceiling effect for pain relief.","indications":["Severe Pain Management"],"catalyst":""},{"name":"Migranal","genericName":"DIHYDROERGOTAMINE","slug":"dihydroergotamine","phase":"marketed","mechanism":"D(3) dopamine receptor","indications":["Cluster headache syndrome","Migraine","Vascular headache"],"catalyst":""},{"name":"Visudyne","genericName":"VERTEPORFIN","slug":"verteporfin","phase":"marketed","mechanism":"Visudyne selectively binds to neovascular tissue, which is then activated by light to induce a phototoxic reaction.","indications":["Choroidal retinal neovascularization","Exudative age-related macular degeneration","Ocular histoplasmosis syndrome","Pathologic Myopia"],"catalyst":""},{"name":"Aldara","genericName":"IMIQUIMOD","slug":"imiquimod","phase":"marketed","mechanism":"Aldara works by activating the immune system to recognize and attack abnormal cells.","indications":["Actinic keratosis","Condyloma acuminatum","Superficial basal cell carcinoma","Verruca"],"catalyst":""},{"name":"Ancobon","genericName":"FLUCYTOSINE","slug":"flucytosine","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 2A","indications":["Serious Candida Infections","Candida Pulmonary Infections","Cryptococcus Meningitis","Cryptococcus Pulmonary Infections","Cryptococcus Septicemia"],"catalyst":""},{"name":"Bepreve","genericName":"BEPOTASTINE","slug":"bepotastine","phase":"marketed","mechanism":"Bepotastine blocks H1 receptors and inhibits histamine release from mast cells.","indications":["Allergic conjunctivitis"],"catalyst":""},{"name":"Besivance","genericName":"BESIFLOXACIN","slug":"besifloxacin","phase":"marketed","mechanism":"Besivance works by inhibiting bacterial DNA replication.","indications":["Bacterial conjunctivitis"],"catalyst":""},{"name":"Dermatop","genericName":"PREDNICARBATE","slug":"prednicarbate","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Atopic dermatitis","Contact dermatitis","Discoid lupus erythematosus","Eruption of skin","Granuloma annulare"],"catalyst":""},{"name":"Edecrin","genericName":"ETHACRYNIC ACID","slug":"ethacrynic-acid","phase":"marketed","mechanism":"Glutathione S-transferase P","indications":["Edema in Congestive Heart Failure","Edema in Cirrhosis of the Liver","Edema in Renal Disease","Ascites Due to Malignancy","Idiopathic Edema"],"catalyst":""},{"name":"Elidel","genericName":"PIMECROLIMUS","slug":"pimecrolimus","phase":"marketed","mechanism":"Elidel works by inhibiting calcineurin, a protein that helps activate T-cells, which are involved in the allergic response.","indications":["Atopic dermatitis","Intractable Eczema"],"catalyst":""},{"name":"Jublia","genericName":"EFINACONAZOLE","slug":"efinaconazole","phase":"marketed","mechanism":"Jublia works by inhibiting the fungal enzyme lanosterol 14α-demethylase, which is essential for the production of ergosterol, a critical component of fungal cell membranes.","indications":["Onychomycosis due to Trichophyton mentagrophytes","Onychomycosis due to dermatophyte","Onychomycosis of toenails"],"catalyst":""},{"name":"Locoid","genericName":"HYDROCORTISONE BUTYRATE","slug":"hydrocortisone-butyrate","phase":"marketed","mechanism":"Locoid works by binding to the glucocorticoid receptor, triggering a response that reduces inflammation and immune responses.","indications":[],"catalyst":""},{"name":"Loprox","genericName":"CICLOPIROX","slug":"ciclopirox","phase":"marketed","mechanism":"Poly [ADP-ribose] polymerase 1","indications":["Onychomycosis Treatment"],"catalyst":""},{"name":"Lotemax","genericName":"LOTEPREDNOL ETABONATE","slug":"loteprednol-etabonate","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Steroid-responsive inflammatory conditions of the eye","Post-operative inflammation following ocular surgery"],"catalyst":""},{"name":"Loteprednol Etabonate","genericName":"LOTEPREDNOL","slug":"loteprednol","phase":"marketed","mechanism":"Small molecule","indications":["allergic conjunctivitis","acne rosacea","superficial punctate keratitis","herpes zoster keratitis","iritis"],"catalyst":""},{"name":"Luzu","genericName":"LULICONAZOLE","slug":"luliconazole","phase":"marketed","mechanism":"Luzu works by inhibiting the growth of fungi by targeting a specific enzyme.","indications":["Tinea corporis","Tinea cruris","Tinea pedis"],"catalyst":""},{"name":"Macugen","genericName":"pegaptanib","slug":"pegaptanib","phase":"marketed","mechanism":"Vascular endothelial growth factor A","indications":["Exudative age-related macular degeneration"],"catalyst":""},{"name":"Miebo","genericName":"PERFLUOROHEXYLOCTANE","slug":"perfluorohexyloctane","phase":"marketed","mechanism":"Miebo works by mimicking the natural oils in the eyes to help maintain moisture.","indications":["Dry Eye Disease"],"catalyst":""},{"name":"Mysoline","genericName":"PRIMIDONE","slug":"primidone","phase":"marketed","mechanism":"Transient receptor potential cation channel subfamily M member 3","indications":["Bipolar disorder in remission","Epilepsy","Epilepsy characterized by intractable complex partial seizures","Lennox-Gastaut syndrome","Localization-related epilepsy"],"catalyst":""},{"name":"Optipranolol","genericName":"METIPRANOLOL","slug":"metipranolol","phase":"marketed","mechanism":"Beta-1 adrenergic receptor","indications":["Ocular hypertension","Open-angle glaucoma"],"catalyst":""},{"name":"Oxsoralen-Ultra","genericName":"METHOXSALEN","slug":"methoxsalen","phase":"marketed","mechanism":"Oxsoralen-Ultra works by generating free radicals when exposed to ultraviolet A (UVA) light, which helps to slow down the growth of skin cells and reduce inflammation.","indications":["Palliative treatment of CTCL skin manifestations"],"catalyst":""},{"name":"Retin-A","genericName":"TRETINOIN","slug":"tretinoin","phase":"marketed","mechanism":"Tretinoin works by binding to and activating nuclear receptors, which helps to regulate cell growth and differentiation.","indications":["Acne vulgaris","Acute promyelocytic leukemia, FAB M3","Chloasma","Facial Fine Wrinkling","Fine Wrinkling"],"catalyst":""},{"name":"Syprine","genericName":"TRIENTINE","slug":"trientine","phase":"marketed","mechanism":"Carbonic anhydrase 14","indications":["Wilson's Disease"],"catalyst":""},{"name":"Targretin","genericName":"BEXAROTENE","slug":"bexarotene","phase":"marketed","mechanism":"Targretin works by binding to the retinoic acid receptor RXR-beta, which helps regulate cell growth and differentiation.","indications":["Primary cutaneous T-cell lymphoma"],"catalyst":""},{"name":"Testred","genericName":"METHYLTESTOSTERONE","slug":"methyltestosterone","phase":"marketed","mechanism":"Androgen receptor","indications":["Bilateral Anorchia","Deficiency of testosterone biosynthesis","Delayed puberty","Hormone receptor positive malignant neoplasm of breast","Inhibition of lactation procedure"],"catalyst":""},{"name":"Vyzulta","genericName":"LATANOPROSTENE BUNOD","slug":"latanoprostene-bunod","phase":"marketed","mechanism":"Vyzulta works by activating the Prostaglandin F2-alpha receptor, which increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure.","indications":["Ocular hypertension","Open-angle glaucoma"],"catalyst":""},{"name":"Xenazine","genericName":"TETRABENAZINE","slug":"tetrabenazine","phase":"marketed","mechanism":"Xenazine works by blocking the reuptake of dopamine and other neurotransmitters into synaptic vesicles, reducing their release and alleviating symptoms of Huntington's chorea.","indications":["Huntington's chorea"],"catalyst":""},{"name":"Xibrom","genericName":"BROMFENAC","slug":"bromfenac","phase":"marketed","mechanism":"Xibrom works by blocking the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.","indications":["Pain","Post-Op Ocular Inflammation","Postoperative Ocular Pain"],"catalyst":""},{"name":"Xiidra","genericName":"LIFITEGRAST","slug":"lifitegrast","phase":"marketed","mechanism":"Xiidra works by blocking the interaction between immune cells and the surface of the eye, reducing inflammation and promoting tear production.","indications":["Tear film insufficiency"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Bausch Health Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Bausch Health reported net sales of $2.6 billion for the fourth quarter of 2023, a decrease of 4% compared to the same period in 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Bausch Health to Acquire Galt Pharmaceuticals","summary":"Bausch Health has entered into a definitive agreement to acquire Galt Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing innovative therapies for various therapeutic areas.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"regulatory","headline":"FDA Approves Bausch Health's Botox for the Treatment of Blepharospasm","summary":"The FDA has approved Bausch Health's Botox for the treatment of blepharospasm, a condition characterized by involuntary eyelid spasms.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPaHNMTmJOVXk4R2JoMm95eWIxWVE5NlFlWHBkV2FpN21ydW9UNmpxMHZlczFCYmdLZ3BCeDkxSUsyRXlndFB1X2d1UkZrbDRQSzd3R0NEOTRIeW8temRTZXFSSzhwUXdER0hrM0ZRRXdkSllSbVpBT1pseHR5TWNNQ3lvU25QbnRaVEJpNEozYy1HWXdtaUUwVzkwOEhBaG1DMGJmbHR1NGdZamtpbzNlMEJyTjBlanJUbUlzcW5wcm9xOGotRWRVUW9R?oc=5","date":"2026-03-02","type":"pipeline","source":"Kalkine Media","summary":"Bausch Health (NYSE:BHC) Stability Story Amid Canada Pharma Shifts Nyse Composite Today - Kalkine Media","headline":"Bausch Health (NYSE:BHC) Stability Story Amid Canada Pharma Shifts Nyse Composite Today","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPc2pUQ19xSGRteS1kY2MtVklwTkhLT25JZlJOdFVCXzc0ZHphRThGZW1WRjdHdmk2SEhscWdqVVptdWYta25XSXEwbXl6SGliV3pzVEhvQ1hSaXVOOE9GZl9PVXJQUHhxZzFFQUdOVjAwWU1vSXhiNDZab1ZPbllVS19WOE9ueVJoRUQtY2w3dENnQQ?oc=5","date":"2026-02-23","type":"pipeline","source":"Yahoo Finance","summary":"Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook - Yahoo Finance","headline":"Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQalhIbkt6eWE2em9QNzdCTk03cW80YjBpbXMteXh2X1NxblQtS29FQllxYnVfUDdKRzhNZXdhMU0wM2xQSU9ZNkZCNFhvVFU1NE5WbHV5VUU0QWV6d2dXX0dTSjNrZnpXcWQ4cElKM1poWXlMRVJJYjFOODJoaTk5T21UUlI3N2ZQeUlSWV9VT1k4QXhYUnVkQ0R6dnRWVkVaZnlid1p6ekoxOXpRY1dOOGE0SEJVTkl1bTAwTU95d29IRUxBSWM0UTV2S09hX2ppV0hqS2Q0Qkg3anNRakFVeExMQ3JDZnZ3ODJEc3FwejQ2SlhQSjhJZ2c0TQ?oc=5","date":"2026-02-23","type":"pipeline","source":"PR Newswire","summary":"Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada - PR Newswire","headline":"Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNUnNYY1V3YjJjSjQzTEZ0SmFnc0tmai1pX2Q4N05MYl9YU1FEWHZ5QnIxdDhScmo4OUU3WWtRNDVJZ1ZCbmlSTGNGV3dENVRidGlhZ3lPTHdfQ0R4SGoyOFFIdGgxbC1RLWYxTE5nZ0dIajV6cFA2WDRPdzJVT2JOb3g4dV9WeG5Sck9aNWZNZ3lnR04tRWN3VG0yS3ZNallCMjBGYnNYWjlPNG11Qk14WQ?oc=5","date":"2026-02-19","type":"pipeline","source":"Stock Titan","summary":"The gum disease antibiotic dentists have used for 25 years, explained - Stock Titan","headline":"The gum disease antibiotic dentists have used for 25 years, explained","sentiment":"neutral"},{"date":"2026-02-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-06","type":"trial","source":"Insider Monkey","summary":"Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results - Insider Monkey","headline":"Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNYnFtLWM4V0xDaHVEb2JmVG8yTnUyN2J5M3hyNXlDYk91VC1PSmZfby1ObUU0U2NfSjZ5REIwMjRhYVBVZFhZSHlERXJobll6T0wtbTNCRVl4UXZDbjFsT29zTEVQellDTVF2Q1pJcFRPWFp0RWdqZ2UwTll6MkdXOUVKWWdVVnJzZndweFIxSGo0UVVKcVoyU20tTzNJSWlzTHR2akl6X1owNlJwSk1qRERITEFIOHRuSGc?oc=5","date":"2026-01-23","type":"trial","source":"PR Newswire","summary":"Bausch Health Provides Update on RED-C Phase 3 Clinical Trials - PR Newswire","headline":"Bausch Health Provides Update on RED-C Phase 3 Clinical Trials","sentiment":"neutral"},{"date":"2026-01-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOWXhJa0h0dVlUenRXSUVvdEkwRy0tQzVaM0dxWjVEMUR0YXV2Q1Z5ekJaR0RMQ29yTzlNdEltTDZLd3J2b1RKMmZJQ2lLYmFNOFZ0MEVlVjdsS1B6NHZrNGpTZTE1S1NHWFY4NUZibjllazRCVEtTa1d3UVNHVm0zM0V2UQ?oc=5","date":"2025-11-13","type":"pipeline","source":"Yahoo Finance","summary":"Bausch Health Companies Inc. (BHC) Announces the Commercial Expansion of OraPharma into Canada and Puerto Rico - Yahoo Finance","headline":"Bausch Health Companies Inc. (BHC) Announces the Commercial Expansion of OraPharma into Canada and Puerto Rico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNa1JuTHpYUnhqb2cyZHNJbHRSVFFlMWQ2aDVrZjhLbGw1akhRdGJ2c3UzLXB5eGkzXzRDYjE3VnRadmVuNEtaWlAtSjFsSHRVbDhsQTI4OWpua05ZcUl1b0VRd3ZsdDRsWkZMU3g0LUZ0ZWFCWG5hejQwVk4tQzdyLXg1NVJFWEJpaTlxRF93?oc=5","date":"2025-09-12","type":"deal","source":"orrick.com","summary":"DURECT Acquired by Bausch Health Companies Inc. - orrick.com","headline":"DURECT Acquired by Bausch Health Companies Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE1NSzNySmVhWUYtVG4tVkFpRmh3S2dmcC1Tcmk3cVdlYTRQODNuWTBlT29EOTJSLVRRd0RsMTlDNmVTd21QS2ExLVg3RXNUV19PYjJ2VU9iUQ?oc=5","date":"2025-08-17","type":"pipeline","source":"TradingView","summary":"BHC Stock Price and Chart — TSX:BHC - TradingView","headline":"BHC Stock Price and Chart — TSX:BHC","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-16","type":"earnings","source":"simplywall.st","summary":"Improved Revenues Required Before Bausch Health Companies Inc. (NYSE:BHC) Stock's 30% Jump Looks Justified - simplywall.st","headline":"Improved Revenues Required Before Bausch Health Companies Inc. (NYSE:BHC) Stock's 30% Jump Looks Justified","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOYlZzeFNMajJ0WHdlT2JmdnRjVjRkZFBVSjhhci1qUm5XSnpiMEJvYlZsbjVkQW8wU2JzUm5ucVJfRWxPb3E2dUpmTmJCRHV0MU50bV9Uai04N1Z1OVptSU1Ec2hUZ2drN05tTE9UMGhodUJpNTJxcmNHcGpJVmxMNjV6ZTd0aDZpQUZIYjRQd3cwUms?oc=5","date":"2025-08-12","type":"pipeline","source":"Seeking Alpha","summary":"Why Bausch Health Stock Surged By Nearly 20% (NYSE:BHC) - Seeking Alpha","headline":"Why Bausch Health Stock Surged By Nearly 20% (NYSE:BHC)","sentiment":"neutral"}],"patents":[{"drugName":"Solodyn","drugSlug":"minocycline","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":400000000},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"8741904","type":"Compound","expiryDate":"2026-02-27","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"10703763","type":"Method of Use","expiryDate":"2026-02-27","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"8518949","type":"Formulation","expiryDate":"2026-02-27","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"9271968","type":"Formulation","expiryDate":"2026-02-27","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"8193196","type":"Compound","expiryDate":"2027-09-02","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Botox","drugSlug":"onabotulinumtoxina","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"10456384","type":"Method of Use","expiryDate":"2029-02-26","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"10765667","type":"Method of Use","expiryDate":"2029-02-26","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"11779571","type":"Method of Use","expiryDate":"2029-02-26","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"11564912","type":"Method of Use","expiryDate":"2029-02-26","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"8309569","type":"Method of Use","expiryDate":"2029-07-18","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"7928115","type":"Method of Use","expiryDate":"2029-07-24","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"8829017","type":"Method of Use","expiryDate":"2029-07-24","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"9421195","type":"Method of Use","expiryDate":"2029-07-24","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"8946252","type":"Method of Use","expiryDate":"2029-07-24","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"10335397","type":"Method of Use","expiryDate":"2029-07-24","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"9629828","type":"Method of Use","expiryDate":"2029-07-24","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"10314828","type":"Method of Use","expiryDate":"2029-07-24","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"10709694","type":"Method of Use","expiryDate":"2029-07-24","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"10238645","type":"Method of Use","expiryDate":"2029-08-18","territory":"US","genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"8598196","type":"Method of Use","expiryDate":"2029-08-18","territory":"US","genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"8642573","type":"Method of Use","expiryDate":"2029-10-02","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Xifaxan","drugSlug":"rifaximin","patentNumber":"8969398","type":"Method of Use","expiryDate":"2029-10-02","territory":"US","annualRevenue":1500000000,"genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"8236816","type":"Method of Use","expiryDate":"2029-12-11","territory":"US","genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"8222270","type":"Method of Use","expiryDate":"2029-12-11","territory":"US","genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"8299109","type":"Method of Use","expiryDate":"2029-12-11","territory":"US","genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"11318130","type":"Method of Use","expiryDate":"2029-12-11","territory":"US","genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"10238644","type":"Method of Use","expiryDate":"2029-12-11","territory":"US","genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"11202752","type":"Method of Use","expiryDate":"2030-04-30","territory":"US","genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"11850245","type":"Method of Use","expiryDate":"2030-04-30","territory":"US","genericFilings":[]},{"drugName":"Aldara","drugSlug":"imiquimod","patentNumber":"10918635","type":"Method of Use","expiryDate":"2030-04-30","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"9056057","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"9532955","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10058511","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"11219596","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"11219597","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"11596599","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10857096","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10864219","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10945948","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10940108","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"9737491","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"9827191","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10993908","type":"Method of Use","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"12115246","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10688045","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"11642317","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10646437","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"9393213","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10646436","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"11872318","type":"Formulation","expiryDate":"2033-05-03","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"11534395","type":"Formulation","expiryDate":"2036-01-26","territory":"US","genericFilings":[]},{"drugName":"Lotemax","drugSlug":"loteprednol-etabonate","patentNumber":"10596107","type":"Formulation","expiryDate":"2036-12-23","territory":"US","genericFilings":[]},{"drugName":"Retin-A","drugSlug":"tretinoin","patentNumber":"10653656","type":"Formulation","expiryDate":"2038-08-22","territory":"US","genericFilings":[]},{"drugName":"Retin-A","drugSlug":"tretinoin","patentNumber":"11324710","type":"Method of Use","expiryDate":"2038-08-22","territory":"US","genericFilings":[]}],"drugCount":32,"phaseCounts":{"marketed":32},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Allergan","Pfizer","Eli Lilly"],"therapeuticFocus":["Dermatology","Gastroenterology"],"financials":{"source":"sec_edgar","revenue":8724000000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":8724000000,"period":"2017-12-31"},{"value":2163000000,"period":"2017-12-31"},{"value":2219000000,"period":"2017-09-30"},{"value":2233000000,"period":"2017-06-30"},{"value":2109000000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":157000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":26366000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":5.36,"previousClose":5.26,"fiftyTwoWeekHigh":8.69,"fiftyTwoWeekLow":4.25,"fiftyTwoWeekRange":"4.25 - 8.69","fiftyDayAverage":5.59,"twoHundredDayAverage":6.45,"beta":0.4,"enterpriseValue":22650159104,"forwardPE":1.3,"priceToBook":-3.58,"priceToSales":0.19,"enterpriseToRevenue":2.21,"enterpriseToEbitda":6.66,"pegRatio":0,"ebitda":3400000000,"ebitdaMargin":33.1,"freeCashflow":1086499968,"operatingCashflow":1400000000,"totalDebt":21078999040,"debtToEquity":5591.2,"currentRatio":1.47,"returnOnAssets":5.2,"returnOnEquity":436.4,"analystRating":"","recommendationKey":"none","numberOfAnalysts":7,"targetMeanPrice":7.71,"targetHighPrice":10,"targetLowPrice":6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":6.52,"exDividendDate":1289347200,"insiderHeldPercent":11,"institutionHeldPercent":66.2,"sharesOutstanding":370562428,"floatShares":222971119,"sharesShort":6296804,"shortRatio":2.61,"shortPercentOfFloat":1.7,"epsTrailing":0.42,"epsForward":4.02,"revenuePerShare":27.68,"bookValue":-1.5,"officers":[{"age":63,"name":"Mr. Thomas J. Appio","title":"CEO & Director"},{"age":60,"name":"Mr. Jean-Jacques  Charhon","title":"Executive VP & CFO"},{"age":52,"name":"Ms. Seana  Carson","title":"Executive VP & General Counsel"},{"age":null,"name":"Ms. Aimee J. Lenar","title":"Executive Vice President of US Pharma"},{"age":null,"name":"Mr. Mirza  Dautbegovic","title":"Executive VP & COO"},{"age":55,"name":"Mr. Steven  Lee","title":"Senior VP, Controller & Chief Accounting Officer"},{"age":null,"name":"Mr. Garen  Sarafian","title":"VP & Head of Investor Relations"},{"age":null,"name":"Ms. Kathleen  Fitzpatrick","title":"Executive VP and Chief HR & Communications Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.bauschhealth.com","phone":"514 744 6792"}}